Share this post on:

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 11/2022”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

As of the end of November 2022 we identify the following current VC trends in Europe:

  • In 2022, overall Life Sciences funding has reached EUR 9,182m so far
  • Top 5 Deals exceed EUR 140m each, largest transaction amounted to EUR 500m in Doctolib (France)
  • Bpifrance (France) dominates the Top 5 Investors (by deal volume), followed by Eurazeo (France) and General Atlantic (United States)
  • Biotech received 44% of the total investment volume, (no change compared to the previous month)
  • Oncology still dominates as the top indication in Biotechnology

To access the full report, please click here.

By Dr. Mathias Schott, Sebastian Sommer and Johannes Link

Source link

Share this post on:

Leave a Comment

Your email address will not be published.